Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Cancer IAfRo. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocaniarcfr/Defaultaspx Accessed March 16, 2017.
- In support of a patient-driven initiative and petition to lower the high price of cancer drugs.Mayo Clin Proc. 2015; 90: 996-1000
- International variation in female breast cancer incidence and mortality rates.Cancer Epidemiol Biomarkers Prev. 2015; 24: 1495-1506
- Quality pathology and laboratory diagnostic services are key to improving global health outcomes: improving global health outcomes is not possible without accurate disease diagnosis.Am J Clin Pathol. 2015; 143: 325-328
- Oncologic care and pathology resources in Africa: survey and recommendations.J Clin Oncol. 2016; 34: 20-26
- Improvement of pathology in sub-Saharan Africa.Lancet Oncol. 2013; 14: e152-e157
- Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply.Arch Pathol Lab Med. 2013; 137: 1723-1732
- Delays in breast cancer presentation and diagnosis at two rural cancer referral centers in Rwanda.Oncologist. 2015; 20: 780-788
- Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa.Breast Cancer Res Treat. 2017; 162: 105-114
- Design considerations for identifying breast cancer risk factors in a population-based study in Africa.Int J Cancer. 2017; 140: 2667-2677
- Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria.Br J Surg. 1999; 86: 665-668
- Temporal trends in breast cancer presentation in the third world.J Exp Clin Cancer Res. 2008; 27: 17
- Epidemiology of breast cancer in Europe and Africa.J Cancer Epidemiol. 2012; 2012: 915610
- Postsurgical management of patients with breast cancer at Kenyatta National Hospital.East Afr Med J. 2002; 79: 156-162
- Epidemiologic and clinical profiles of breast diseases in Niger.Int J Cancer Oncol. 2015; 2
- Benign and malignant breast disease at Rwanda's first public cancer referral center.Oncologist. 2016; 21: 571-575
- Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.N Engl J Med. 1989; 320: 822-828
- Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants.Cancer. 1993; 71: 2507-2514
- Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.J Clin Oncol. 1989; 7: 1239-1251
- Long-term recurrence risks after use of endocrine therapy for only 5 years: relevance of breast tumor characteristics.J Clin Oncol. 2016; 34 (abstr 505)
- Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.J Clin Oncol. 2008; 26: 3153-3158
- Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study.J Clin Oncol. 2001; 19: 28-36
- Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program.Arch Pathol Lab Med. 2014; 138: 1048-1052
- Histological types of breast cancer: how special are they?.Mol Oncol. 2010; 4: 192-208
- Tubular carcinoma of the breast: further evidence to support its excellent prognosis.J Clin Oncol. 2010; 28: 99-104
- Invasive breast cancer: a significant correlation between histological types and molecular subgroups.J Cancer Res Clin Oncol. 2013; 139: 617-623
- Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.Oncologist. 2014; 19: 805-813
- The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast.Br J Cancer. 1985; 51: 263-270
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet. 2005; 365: 1687-1717
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).Arch Pathol Lab Med. 2010; 134: e48-e72
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.J Clin Oncol. 2010; 28: 2784-2795
- The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.Mod Pathol. 2012; 25: 1098-1105
- The effect of cold ischemia time and/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma.Patholog Res Int. 2012; 2012: 947041
- Frozen section library: breast.Springer, New York2012
- Triple-negative breast cancer in African-American women: disparities versus biology.Nat Rev Cancer. 2015; 15: 248-254
- Triple-negative breast cancer in Ghanaian women: the Korle Bu Teaching Hospital experience.Breast J. 2015; 21: 627-633
- Characterizing breast cancer in a population with increased prevalence of triple-negative breast cancer: androgen receptor and ALDH1 expression in Ghanaian women.Ann Surg Oncol. 2015; 22: 3831-3835
- Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa.Breast Cancer Res Treat. 2013; 140: 177-186
- Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.BMC Womens Health. 2012; 12: 35
- Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis.PLoS Med. 2014; 11: e1001720
- Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.J Clin Oncol. 2009; 27: 4515-4521
- Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.Breast Cancer Res. 2013; 15: R84
- Immunohistochemical and molecular subtypes of breast cancer in Nigeria.Breast Cancer Res Treat. 2008; 110: 183-188
- Quality of breast cancer treatment at a rural cancer center in Rwanda.J Glob Oncol. 2017; ([Epub ahead of print])
- Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration.BMC Cancer. 2016; 16: 204
- Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.Anal Quant Cytol Histol. 2006; 28: 97-103
- Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.Breast. 2014; 23: 591-596
- Proposing essential medicines to treat cancer: methodologies, processes, and outcomes.J Clin Oncol. 2016; 34: 69-75
WHO to begin pilot prequalification of biosimilars for cancer treatment. Press Release 4 May 2017. Available at: http://wwwwhoint/mediacentre/news/releases/2017/pilot-prequalification-biosimilars/en/. Accessed May 17, 2017.
- Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial.JAMA. 2017; 317: 37-47
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol. 1998; 16: 2672-2685
- Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National surgical adjuvant breast and bowel project protocol B-27.J Clin Oncol. 2006; 24: 2019-2027
- Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657.J Clin Oncol. 2012; 30: 3242-3249
- Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype.J Clin Oncol. 2017; 35: 1049-1060
- Influence of delay on survival in patients with breast cancer: a systematic review.Lancet. 1999; 353: 1119-1126
- Diagnosis of cancer in rural Rwanda: early outcomes of a phased approach to implement anatomic pathology services in resource-limited settings.Am J Clin Pathol. 2014; 142: 541-545
- Cancer pathology turnaround time at Queen Elizabeth Central Hospital, the largest referral center in Malawi for oncology patients.J Glob Oncol. 2017; ([Epub ahead of print])
- Intralaboratory timeliness of surgical pathology reports. Results of two College of American Pathologists Q-Probes studies of biopsies and complex specimens.Arch Pathol Lab Med. 1996; 120: 234-244
- 10-year analysis of the ATAC trial: wrong conclusion?.Lancet Oncol. 2011; 12 ([author reply: 7]): 216-217
- Extending aromatase-inhibitor adjuvant therapy to 10 years.N Engl J Med. 2016; 375: 209-219
- Implementation and validation of telepathology triage at cancer referral center in rural Rwanda.J Glob Oncol. 2016; 2: 76-82
- Joining forces to overcome cancer: the Kenya cancer research and control stakeholder program.J Cancer Policy. 2016; 7: 36-41
- High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX.Cancer Res. 2017; 77 ([abstract: P1-03-03])
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA. 2006; 295: 1658-1667
- Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group.Eur J Cancer. 1999; 35: 32-38
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N Engl J Med. 2004; 351: 2817-2826
- Prospective validation of a 21-gene expression assay in breast cancer.N Engl J Med. 2015; 373: 2005-2014
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.Lancet Oncol. 2010; 11: 55-65
- Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry.Cancer Res. 2017; 77
Article info
Publication history
Published online: December 13, 2017
Footnotes
Disclosure Statement: J.E. Brock received research funding from Cepheid. Y.M. Martei, L.E. Pace, and L.N. Shulman have nothing to disclose.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
